Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.80 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801184 | 0.89 | MET (0.80) | METCYP3A4ABL1 | |
| SCHEMBL3804115 | 0.89 | MET (1.00) | METCYP3A4ABL1 | |
| SCHEMBL611705 | 0.89 | MET (1.00) | METCYP3A4ABL1 | |
| SCHEMBL2801802 | 0.88 | MET (0.79) | METCYP3A4ABL1 | |
| SCHEMBL2576731 | 0.88 | MET (0.65) | METCYP3A4 | |
| SCHEMBL3809319 | 0.88 | MET (0.95) | METCYP3A4ABL1 | |
| SCHEMBL2802346 | 0.87 | MET (0.87) | METCYP3A4ABL1 | |
| SCHEMBL2763415 | 0.87 | MET (0.82) | METCYP3A4ABL1 | |
| SCHEMBL3805631 | 0.87 | MET (1.00) | METCYP3A4ABL1 | |
| SCHEMBL3808844 | 0.87 | MET (0.97) | METCYP3A4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011121223-A1 | 6-(ALKYL- OR CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLE DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | WO | claimed |
| WO-2011121223-A1 | 6-(ALKYL- OR CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLE DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | WO | disclosed |